Excellent long-term survival of 170 patients with Waldenström's macroglobulinemia treated in private oncology practices and a university hospital

Annals of Hematology

Volumn 91, Issue 12, 2012, Pages 1923-1928

  Hensel, M ^a   Brust, J ^a   Ploger C ^a   Schuster, D ^a   Memmer, M L ^b   Franz Werner, J ^d   Feustel, H P ^d   Karcher, A ^e   Fuxius, S ^e   Mosthaf, F A ^c   Rieger, M ^b   Ho, A D ^b   Witzens Harig, M ^b  

^a Mannheimer Onkologie Praxis   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Onkologische Schwerpunktpraxis   (Germany)

^d Onkologische Schwerpunktpraxis Speyer   (Germany)

^e Onkologische Schwerpunktpraxis   (Germany)

Author keywords

Long term survival; Private practice; Treatment; University hospital; Waldenstr m's macroglobulinemia

Indexed keywords

BENDAMUSTINE; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; INTERFERON; MELPHALAN; MITOXANTRONE; PENTOSTATIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GERMANY; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; PRIVATE PRACTICE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DELAYED DIAGNOSIS; FEMALE; GERMANY; HOSPITALS, UNIVERSITY; HUMANS; MALE; MEDICAL ONCOLOGY; MEDICAL RECORDS; MIDDLE AGED; PRIVATE PRACTICE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; URBAN HEALTH; WALDENSTROM MACROGLOBULINEMIA;

EID: 84871019046     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1545-8     Document Type: Article

References (30)

1. Baehring JM, Hochberg EP et al (2008) Neurological manifestations of Waldenstrom macroglobulinemia. Nat Clin Pract Neurol 4 (10):547-556
2. Berentsen S (2009) Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 9(1):110-112
3. Buske C, Hoster E et al (2009) The addition of rituximab to frontline therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 23 (1):153-161
4. Dimopoulos MA, Anagnostopoulos A et al (2007) Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25(22):3344-3349
5. Gertz MA (2010) Current status of stem cell mobilization. Br J Haematol 150(6):647-662
6. Gertz MA, Kyle RA et al (1993) Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglobulinemia. J Clin Oncol 11 (5):914-920
7. Gertz MA, Rue M et al (2004) Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 45 (10):2047-2055
8. Gertz MA, Reeder CB et al. (2011) Stem cell transplant for Waldenstrom macroglobulinemia: an underutilized technique. Bone Marrow Transplant. doi:10.1038/bmt.2011.175
9. Ghobrial IM, Uslan DZ et al (2004) Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenstrom macroglobulinemia does not indicate failure of response. Am J Hematol 77(4):329-330
10. Ghobrial IM, Gertz M et al (2010) Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 28 (8):1408-1414
11. Ghobrial IM, Hong F et al (2010) Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 28 (8):1422-1428
12. Grant S (2011) Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors. Leuk Lymphoma 52(9):1623-1625
13. Hensel M, Villalobos M et al (2005) Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 6(2):131-135
14. Hivert B, Tamburini J et al (2011) Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia. Haematologica 96(5):785-788
15. Hutchins LF, Unger JM et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061-2067
16. Ioakimidis L, Patterson CJ et al (2009) Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 9(1):62-66
17. Issa GC, Ghobrial IM et al (2011) Novel agents in Waldenstrom macroglobulinemia. Clin Investig (Lond) 1(6):815-824
18. Kyle RA, Garton JP (1987) The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 62(8):719-731
19. Kyle RA, Treon SP et al (2003) Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop onWaldenstrom's Macroglobulinemia. Semin Oncol 30(2):116-120
20. Loberiza FR Jr, Cannon AJ et al (2009) Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study. J Clin Oncol 27 (32):5376-5382
21. Morel P, Duhamel A et al (2009) International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113 (18):4163-4170
22. Owen RG, Treon SP et al (2003) Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30(2):110-115
23. Peinert S, Tam CS et al (2010) Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenstrom macroglobulinemia. Leuk Lymphoma 51(12):2188-2197
24. Pisters PW, Blanke CD et al (2011) A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Ann Oncol 22(11):2523-2529
25. Roccaro AM, Sacco A et al (2010) Dual targeting of the PI3K/Akt/ mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 115(3):559-569
26. Rummel M (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to chop plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 114(22), ASH Annual Meeting Abstract 405
27. Stone MJ (2009) Waldenstrom's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin Lymphoma Myeloma 9 (1):97-99
28. Tedeschi A, Alamos SM et al (2009) Fludarabine-based combination therapies for Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 9(1):67-70
29. van Oost FJ, Luiten EJ et al (2006) Outcome of surgical treatment of pancreatic, peri-ampullary and ampullary cancer diagnosed in the south of The Netherlands: a cancer registry based study. Eur J Surg Oncol 32(5):548-552
30. Wong SJ, Harari PM et al (2011) Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. Cancer 117 (8):1679-1686